“…In the last few years, our investigations have been focus on the Ru(II)-imidazole/methylimidazole compounds including their design, synthesis, structural modification, biological activity, and underlying behaviour mechanisms [10–15]. In previous studies, Ru(II) methylimidazole complexes, with the general formula [Ru(MeIm) 4 (L)] 2+ (L = dpq, dppz, iip, tip, cpip), showed strong DNA-binding affinities and some antitumor activities [10–14]. It is worth noting that the homologous complex Ru1 (Figure 1A) bearing imidazole as the ancillary ligand synthesised in our laboratory, differs from other ruthenium (II) methylimidazole complexes in the circular dichroic spectrum of DNA–complex adducts, and so on [10].…”